Combined Hepatocellular-cholangiocarcinoma
3
1
1
0
Key Insights
Highlights
Treatment Research
4 treatments under study, led by Observation
Research Leaders
9 sponsors active, led by Eastern Hepatobiliary Surgery Hospital
Related Conditions
Often studied with 6 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 3 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (3)
Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therapy for Combined Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data
Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer
Research Network
Common Treatments
- Observation1
- Cadonilimab1
- Capecitabine1
- Interventional Therapies Combined With Or Without Systemic Drugs1
Active Sponsors
- Eastern Hepatobiliary Surgery Hospital2
- Shanghai Zhongshan Hospital2
- Jiangsu Cancer Institute & Hospital1
- The First Affiliated Hospital of Zhengzhou University1
- Yunnan Cancer Hospital1
Top Investigators
Eastern Hepatobiliary Surgery Hospital, Second Military Medical University
Zhongda hospital, Southeast university, Nanjing, China
Related Conditions
- Combined Hepatocellular Carcinoma And Cholangiocarcinoma1
- Intrahepatic Cholangiocarcinoma1
- Hepatocellular Carcinoma1
- Liver Neoplasms1
- Combined Hepatocellular And Cholangiocarcinoma1